Tumor-in-host Dynamic Energy Budget (DEB)-based approach
Can one describe tumor and host body responses to the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib and the MET inhibitors capmatinib and S49076 in
Can one describe tumor and host body responses to the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib and the MET inhibitors capmatinib and S49076 in
Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions..